Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

  • Cash runway remains into Q4 2027, supporting continued funding of clinical programs and pre-commercial planning activities
  • Royalty overhang materially reduced, enhancing financial flexibility to support future commercialization efforts